Related Experiment Video
Updated: May 30, 2026

Interactions with and Membrane Permeabilization of Brain Mitochondria by Amyloid Fibrils
Published on: September 28, 2019
Dysregulation of miRNAs in AL amyloidosis
Liangping Weng1, Brian H Spencer, Pamela T SoohHoo
1Amyloid Treatment and Research Program, Boston University School of Medicine and Boston Medical Center, Boston, MA, USA.
Abstract:
Bone marrow plasma cells (BMPCs) were purified using anti-CD138 immunomagnetic beads, from aspirates obtained with permission of the Boston University Medical Campus Institutional Review Board, from patients with immunoglobulin light chain (AL) amyloidosis and from controls. Expression levels of MicroRNAs (miRNAs) were compared by microarray; 10 were found to be increased more than 1.5-fold. These results were confirmed using stem-loop RT-qPCR for the most highly upregulated miRNAs, miR-148a, miR-26a, and miR-16. miR-16, a micro-RNA linked to other hematopoietic diseases, was significantly increased in the AL group at diagnosis, and also in treated patients with persistent monoclonal plasma cells in the bone marrow, but not in patients who achieved a hematologic remission after therapy. miR-16 can be derived from the miR-16-1/mirR-15, a cluster on chromosome 13 or the miR-16-2/miR-15b cluster on chromosome 3. The expression of miR-15b was much higher than miR-15a in both AL and control BMPC, suggesting that miR-16 in plasma cells is mainly derived from miR-16-2/miR-15b. The anti-apoptosis gene BCL-2, a putative target mRNA that can be downregulated by miR-16, was expressed in BMPCs from AL patients, despite elevated levels of miR-16. Our data suggests that miRNAs are dysregulated in clonal plasma cells in AL amyloidosis and may be potentially useful as biomarkers of disease.
Insights
MicroRNAs (miRNAs) are dysregulated in immunoglobulin light chain (AL) amyloidosis. Specifically, miR-16 levels are elevated in patients with AL amyloidosis, suggesting potential use as disease biomarkers.
Area of Science:
- Hematology
- Molecular Biology
- Genetics
Background:
- Immunoglobulin light chain (AL) amyloidosis is a plasma cell disorder.
- MicroRNAs (miRNAs) play crucial roles in cellular processes and disease pathogenesis.
- Dysregulation of miRNAs in bone marrow plasma cells (BMPCs) is implicated in various hematologic malignancies.
Purpose of the Study:
- To investigate miRNA expression profiles in BMPCs from patients with AL amyloidosis.
- To identify specific miRNAs that are differentially expressed in AL amyloidosis compared to controls.
- To explore the potential of these miRNAs as diagnostic or prognostic biomarkers for AL amyloidosis.
Main Methods:
- Purification of BMPCs from AL amyloidosis patients and controls using anti-CD138 immunomagnetic beads.
- Microarray analysis to compare miRNA expression levels.
- Validation of key miRNA candidates using stem-loop RT-qPCR.
Main Results:
- Ten miRNAs were found to be upregulated more than 1.5-fold in AL amyloidosis BMPCs.
- miR-16 was significantly increased in AL amyloidosis patients at diagnosis and in those with persistent disease, but not in remission.
- Expression of miR-15b was higher than miR-15a, suggesting miR-16 is mainly derived from the miR-16-2/miR-15b cluster.
- The anti-apoptosis gene BCL-2 was expressed in AL amyloidosis BMPCs despite elevated miR-16 levels.
Conclusions:
- miRNAs are dysregulated in clonal plasma cells in AL amyloidosis.
- Specific miRNAs, such as miR-16, show altered expression patterns correlating with disease status.
- These dysregulated miRNAs may serve as potential biomarkers for AL amyloidosis.
More Related Videos
Related Concept Videos
MicroRNAs
MicroRNAs
Amyloid Fibrils
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining, normally used to...
Neural Regulation
Alzheimer Disease ll: Pathophysiology

